BioMarin Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3,221	2,854	2,419	2,096	1,846
Revenue Growth (YoY)	12.87%	17.97%	15.42%	13.53%	-0.76%
Cost of Revenue	598.23	580.24	532.06	1,153	1,099
Gross Profit	2,623	2,274	1,887	943.41	746.97
Selling, General & Admin	1,031	1,009	892.41	823.24	759.38
Research & Development	921.93	747.18	746.77	-	-
Amortization of Goodwill & Intangibles	19.39	43.26	62.21	65.49	61.91
Operating Expenses	1,972	1,799	1,701	888.73	821.28
Operating Income	650.73	474.21	185.77	54.68	-74.32
Interest Expense	-10.9	-12.67	-17.34	-15.97	-15.34
Interest & Investment Income	74.9	74.88	58.34	18.03	10.48
Currency Exchange Gain (Loss)	-	-	-	-11.4	-
Other Non Operating Income (Expenses)	9	-4.67	-38.22	-2.06	11.85
EBT Excluding Unusual Items	723.73	531.76	188.56	43.28	-67.32
Merger & Restructuring Charges	-241.25	-	-	-	-
Gain (Loss) on Sale of Assets	-	10	-	108	-
Other Unusual Items	-	-	-	-1.7	-8.03
Pretax Income	482.48	541.76	188.56	149.58	-75.35
Income Tax Expense	133.58	114.9	20.92	8.02	-11.27
Net Income	348.9	426.86	167.65	141.56	-64.08
Net Income to Common	348.9	426.86	167.65	141.56	-64.08
Net Income Growth	-18.26%	154.62%	18.43%	-	-
Shares Outstanding (Basic)	192	190	188	185	183
Shares Outstanding (Diluted)	197	197	192	189	183
Shares Change (YoY)	0.35%	2.67%	1.39%	3.34%	-4.61%
EPS (Basic)	1.82	2.25	0.89	0.76	-0.35
EPS (Diluted)	1.80	2.21	0.87	0.75	-0.35
EPS Growth	-18.24%	153.71%	16.00%	-	-
Free Cash Flow	724.96	487.42	62.57	54.94	208.96
Free Cash Flow Per Share	3.67	2.48	0.33	0.29	1.14
Gross Margin	81.43%	79.67%	78.01%	45.01%	40.46%
Operating Margin	20.20%	16.62%	7.68%	2.61%	-4.03%
Profit Margin	10.83%	14.96%	6.93%	6.75%	-3.47%
Free Cash Flow Margin	22.50%	17.08%	2.59%	2.62%	11.32%
EBITDA	722.89	570.64	290.16	156.65	33.72
EBITDA Margin	22.44%	19.99%	11.99%	7.47%	1.83%
D&A For EBITDA	72.16	96.43	104.39	101.97	108.04
EBIT	650.73	474.21	185.77	54.68	-74.32
EBIT Margin	20.20%	16.62%	7.68%	2.61%	-4.03%
Effective Tax Rate	27.69%	21.21%	11.09%	5.36%	-
Revenue as Reported	3,221	2,854	2,419	2,096	1,846
Advertising Expenses	50.5	34.5	27.8	25.2	30.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.